Biomarkers of angiogenesis and their role in the development of VEGF inhibitors


Vascular endothelial growth factor (VEGF) has been confirmed as an important therapeutic target in randomised clinical trials in multiple disease settings. However, the extent to which individual patients benefit from VEGF inhibitors is unclear. If we are to optimise the use of these drugs or develop combination regimens that build on this efficacy, it is… (More)
DOI: 10.1038/sj.bjc.6605483


4 Figures and Tables